An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

ClinicalTrials.gov ID: NCT07161700

Public ClinicalTrials.gov record NCT07161700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 19, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults With Major Depressive Disorder, With or Without Anxious Distress

Study identification

NCT ID: NCT07161700
Recruitment status: Enrolling by invitation
Study type: Interventional
Phase: Phase 2
Lead sponsor: Seaport Therapeutics; Industry
Enrollment: 360 participants

Conditions and interventions

Conditions

Interventions

SPT-300 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 66 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 1, 2025
Primary completion: Apr 30, 2027
Completion: Apr 30, 2027
Last update posted: May 18, 2026

2025 – 2027

United States locations

U.S. sites: 13
U.S. states: 8
U.S. cities: 13

Facility	City	State	ZIP	Site status
Seaport Investigator Site	Chino	California	91710	—
Seaport Investigator Site	Garden Grove	California	92845-2506	—
Seaport Investigator Site	Glendale	California	91206	—
Seaport Investigator Site	West Palm Beach	Florida	33407	—
Seaport Investigator Site	Atlanta	Georgia	30328	—
Seaport Investigator Site	Decatur	Georgia	30030	—
Seaport Investigator Site	Boston	Massachusetts	02116	—
Seaport Investigator Site	St Louis	Missouri	63141	—
Seaport Investigator Site	Brooklyn	New York	11235	—
Seaport Investigator Site	New York	New York	10029	—
Seaport Investigator Site	Staten Island	New York	10314	—
Seaport Investigator Site	North Canton	Ohio	44720	—
Seaport Investigator Site	Irving	Texas	75062	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07161700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 18, 2026 · Synced May 19, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07161700 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →